The basic objective of this proposal will be to measure the ex vivo fitness of HIV- 1 isolates from individuals infected with clade B and non-clade B HIV-1 and then compare this fitness to various predictors of disease progression. A pilot study revealed a strong correlation between ex vivo HIV-1 fitness and viral load. To extend this study, multiple HIV-1 isolates from approximately 80 HIV-infected individuals have been obtained from the Karolinska Insititute in Sweden and at the :Institute of Tropical Medicine in Antwerp, Belgium.
In SPECIFIC AIM 1, we will compete each patient isolate with our control HIV-1 strains to determine a relative ex vivo fitness value. These fitness values will then be compared to various clinical parameters such as CD4 cell counts and viral load. The objective of this aim is to extend a previous pilot study showing a strong correlation between HIV-1 fitness and disease progression. Ultimately the rate of intrapatient disease progression may play a role in distribution of HIV-1 isolates or subtypes in the epidemic.
SPECIFIC AIM 2 is to compare differences in intra- and intersubtype fitness. The fitness of multiple isolates from clades A, B, C, and D via pair-wise competitions in peripheral blood mononuclear cells. Preliminary data suggests a greater difference between isolates of different subtypes than of the same subtype. Thus, in SPECIFIC AIM 3, we will investigate if possible differences in subtype fitness may affect disease progression in non-clade B infections. As in aim 1, the ex vivo fitness of primary HIV-1 isolates from approximately 150 HIV-infected Ugandans and Zimbabweans (participating in an NICHD-funded study) will be compared to various predictors of disease progression. Since virus will be first obtained from both blood and vaginal secretions during primary infection, we will also perform intersubtype competition experiments using Langerhan cells. Viral propagation for fitness studies is a laborious technique that may be circumvented with the experiments proposed in SPECIFIC AIM 4. Using an assay to look at multiple steps in the HIV-1 replication cycle during dual virus infections, we now have preliminary data to suggest that HIV-1 entry may be controlling the competition. We will confirm this preliminary observation in SPECIFIC AIM 4 and then use a novel cloning strategy to produce HIV-1 NL4-3 clones pseudotyped with env genes directly from patient samples. Competitions between these env pseudotyped HIV-1 clones will then be compared to competitions between two propagated HIV-1 isolates from the same two patient samples.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI049170-01A1
Application #
6409571
Study Section
Special Emphasis Panel (ZRG1-AARR-1 (01))
Program Officer
Young, Janet M
Project Start
2001-09-27
Project End
2002-09-26
Budget Start
2001-09-27
Budget End
2002-09-26
Support Year
1
Fiscal Year
2001
Total Cost
$265,455
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Krebs, Kendall C; Tian, Meijuan; Asmal, Mohammed et al. (2016) Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections. AIDS Res Ther 13:41
Kyeyune, Fred; Gibson, Richard M; Nankya, Immaculate et al. (2016) Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure. Antimicrob Agents Chemother 60:3380-97
Choi, Eunsil; Michalski, Chad J; Choo, Seung Ho et al. (2016) First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. Retrovirology 13:82
Bagaya, Bernard S; Vega, José F; Tian, Meijuan et al. (2015) Functional bottlenecks for generation of HIV-1 intersubtype Env recombinants. Retrovirology 12:44
Rubio, Andrea E; Abraha, Awet; Carpenter, Crystal A et al. (2014) Similar replicative fitness is shared by the subtype B and unique BF recombinant HIV-1 isolates that dominate the epidemic in Argentina. PLoS One 9:e92084
Chamanian, Mastooreh; Purzycka, Katarzyna J; Wille, Paul T et al. (2013) A cis-acting element in retroviral genomic RNA links Gag-Pol ribosomal frameshifting to selective viral RNA encapsidation. Cell Host Microbe 13:181-92
Ratcliff, Annette N; Shi, Wuxian; Arts, Eric J (2013) HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120. J Virol 87:923-34
Lobritz, Michael A; Ratcliff, Annette N; Marozsan, Andre J et al. (2013) Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc. Antimicrob Agents Chemother 57:2640-50
Kyeyune, Fred; Nankya, Immaculate; Metha, Samar et al. (2013) Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. AIDS 27:1899-909
Arts, Eric J (2012) Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication. BMC Med 10:114

Showing the most recent 10 out of 21 publications